Future Research With CAR T Therapy in Multiple Myeloma: Frits van Rhee, MD, PhD
The professor and director of the myeloma center at the University of Arkansas for Medical Sciences discussed future research with CAR T in multiple myeloma.
Reduced Response to Adoptive Transfer of TIL Therapy in Metastatic Melanoma With Prior Treatment
Adoptive transfer of TILs elicited an ORR of 56% in patients with metastatic melanoma who were naïve to PD-1 inhibitors compared with 24% in patients refractory to PD-1 inhibitors.
Elucidating the Role of HTRA1 in Developing AMD: Gregory S. Hageman, PhD; Brandi L. Williams, PhD
Directors from the Moran Eye Center discussed their research on the genetics of age-related macular degeneration.
Addressing High Relapse Rates in CAR T-Cell Therapy
Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s CAR T Engager protein technology.
PKU Gene Therapy Trial on Clinical Hold Following Tumor Development in Mice
Six of 7 mice treated with a new, higher dose of BMN-307 showed tumors in liver necropsy at 52 weeks post-treatment.
New Gene Therapy Collaboration Targets Huntington Disease
NeuExcell and Spark Therapeutics each add to their gene therapy pipelines with the collaborative program.
Rationale and Future of Ide-Cel: Larry D. Anderson, Jr, MD, PhD
The hematologist/oncologist at the Harold C. Simmons Comprehensive Cancer Center discussed the rationale behind using CAR T-cell therapy in relapsed/refractory multiple myeloma and data from the KarMMa trial.
Gene Therapy's Potential in Retinal Disease
A new animal model will facilitate the study and development of gene therapies in retinal diseases.
Emerging Therapeutics Optimize Hematologic Malignancy Treatment
Experts discussed novel options such as CAR T-cell therapy for optimizing treatment in MCL, myelofibrosis, and ALL.
CARTITUDE Trials in Multiple Myeloma
Experts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
Gene Therapy Partially Restored Vision in Patient with Retinitis Pigmentosa
Addressing Unmet Needs With Gene Therapy
Eric Crombez, PhD, senior vice president and chief medical officer of Ultragenyx Gene Therapy, discussed indications the company is targeting.
Gavo-Cel Granted Orphan Drug Designation for Cholangiocarcinoma
The investigational cell therapy consists of T-cell receptor (TCR) fusion construct T cells (TRuC-T cells).
Gene Therapy for Retinal and Neurological Diseases
Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed future research the company plans to pursue.
Recruitment Resumed in Gene Therapy Trial for Ovarian Cancer
The FDA has cleared a batch of VB-111 manufactured in Modiin, Israel, following a technical review.
Investigational Agents in Relapsed/Refractory Myeloma
Experts discuss emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Severe Neurodegenerative, Epileptic Disorders the Target of Taysha Gene Therapies
With numerous targets in CNS diseases and a unique partnership with gene therapy experts at UT Southwestern, Taysha is hoping to fill significant unmet needs.
Autologous Hematopoietic Stem Cell Transplant Shows Durable Response in Mantle Cell Lymphoma
A post-hoc analysis overviewed long-term efficacy of autologous hematopoietic stem cell transplantation in mantle cell lymphoma.
Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia
The hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.
Poseida’s CAR-T Cell Therapy for Prostate Cancer Shows Promising Durable Response in Phase 1
The early-phase data readout follows news that the FDA recently approved its IND for its CAR-T candidate in multiple myeloma.
Treatment Options in Transplant-Ineligible DLBC Lymphoma
Experts discussed treatment for patients with transplant-ineligible diffuse large B-cell lymphoma.
Race to Treat GM1 Gangliosidosis With Gene Therapy Continues
The first US-based patient has been dosed in Lysogene’s clinical trial of LYS-GM101, following 2 other competing trials.
Future CAR T Therapy Research in Multiple Myeloma: Krina K. Patel, MD, MSc
The associate professor from The University of Texas MD Anderson Cancer Center discussed future research with CAR T therapy in multiple myeloma.
Allogeneic HSCT Significantly Improves EF Survival in Patients With MDS
Patients with MDS treated with alloHSCT and 5-aza had significant improvements in event-free survival compared to 5-aza treatment alone.
Emerging Data in Diffuse Large B-Cell Lymphoma
Experts discussed data from trials in lymphoma presented at ASCO 2021.
The State of Retina Therapeutics
An international panel of experts discussed needs and challenges in the field.
CAR T-Cell Therapy's Potential in Non-Hodgkin Lymphoma: Julie Vose, MD
The chief of Oncology and Hematology at University of Nebraska Medical Center, discussed the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma (NHL) paradigm.
2021 CAR-TCR Summit Elevates Industry Expertise in Cell Therapies
The 4-day virtual conference will feature plenary presentations, workshops, and bootcamps led by cell therapy industry leaders with expertise in discovery, development, manufacturing, and more.
Utilizing CRISPR Technology to Develop Cell Therapies for Diabetes, Blood Diseases
Both Vertex and Arbor are adding to their list of gene and cell therapy partnerships with the announcement.
Using A Modular Approach to Develop Oncolytic Cell Therapies
The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.
